Compare Abbott Laboratories (ABT) vs First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Abbott Laboratories trades at $95.16 (market cap $166.94B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $54.9. The key difference: Abbott Laboratories pays a 2.63% dividend while First Trust NASDAQ Clean Edge Green Energy Idx Fd pays none, and First Trust NASDAQ Clean Edge Green Energy Idx Fd is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | QCLN | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $68.47 |
52-Week Low | $82.57 | $34.04 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.18, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. The stock shows solid fundamentals with a P/E of 26.85, net income margin of 13.91%, and consistent dividend payments. Recent news highlights CE Mark approval for Libre Duo systems and positive diagnostic portfolio developments, supporting growth prospects in healthcare markets.
Outlook remains positive with a consensus price target of $122.55 implying 29% upside, though risks include competitive pressures and macroeconomic volatility. Earnings beat in Q1 2026 offsets prior misses, while cash flow stability and declining debt-to-asset ratio (15.02% in 2025) reinforce financial health. Institutional sentiment is strongly bullish with 75.6% buy ratings.
QCLN trades at $58.70, up 3.51% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF faces mixed sentiment amid clean energy sector volatility, with support at $55 and resistance at $60. Recent news highlights policy risks from stalled US permits and geopolitical tensions affecting solar supply chains, while global investment in renewables continues to grow.
Outlook remains cautious due to regulatory headwinds and cost pressures, though long-term clean energy demand provides upside potential. Key risks include US-China trade policies and inflation-driven installation costs, with investor sentiment divided between near-term challenges and structural growth opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →
